SHERIDAN, WYOMING – May 1, 2025 – Straumann Group has reported robust financial performance for the first quarter of 2025, achieving CHF 680.7 million in revenue and 11.0% organic growth, affirming its strategic momentum despite ongoing macroeconomic uncertainties. Driven by double-digit gains in EMEA and APAC, alongside significant digital dentistry advancements, the Group has confirmed its 2025 outlook and reaffirmed its position as a global leader in implantology and orthodontics.
Solid Regional Performance Underscores Market Resilience
The Group's strong results were underpinned by varied regional dynamics, with notable performance in:
- EMEA (CHF 280.0 million): Delivered 10.0% organic growth, led by sustained demand in Germany, Italy, Spain, and Belgium. ClearCorrect orthodontics and biomaterials also showed strong traction.
- APAC (CHF 162.2 million): Achieved record revenue with 23.0% organic growth, largely due to momentum in China and strong uptake in Thailand, India, and Malaysia.
- LATAM (CHF 53.4 million): Posted 18.8% organic growth, driven by Neodent and ClearCorrect performance in Brazil and Mexico.
- North America (CHF 185.1 million): Recorded modest 1.8% organic growth amid a soft US implantology market and cautious consumer spending. New digital and implant system launches supported positive contributions.
CEO Guillaume Daniellot emphasized the company’s strategic adaptability:
“I’m proud of our team and the strong momentum we have built, driven by our high-performance, player-learner culture — a key element in helping us stay agile and adapt in a fast-changing environment,” he said. “We are well positioned — both in terms of our diversified portfolio and broad geographic presence — to build on our strengths and drive long-term success.”
Breakthrough Innovations in Digital Dentistry Take Center Stage at IDS
At the 2025 International Dental Show (IDS) in Cologne, Straumann unveiled its most comprehensive digital dentistry offering to date, centered around its cloud-based Straumann AXS platform. The platform unifies solutions such as:
- Smile-in-a-Box: An all-in-one digital treatment planning and delivery solution.
- UN!Q: A cloud-based prosthetics service enabling efficient outsourcing for dental labs.
- SIRIOS Intraoral Scanner and coDiagnostiX AI planning software: Supporting a seamless, fully integrated end-to-end digital workflow.
These innovations drew strong interest from clinicians seeking faster, more predictable treatment outcomes.
Strategic Collaborations Elevate Chairside Efficiency
Straumann further bolstered its digital ecosystem through key partnerships:
- SprintRay: The co-branded Straumann Signature Midas 3D printer enables in-office prosthetic printing in under 10 minutes, integrated with AXS and SIRIOS for chairside convenience.
- Carestream Dental: Enables seamless CBCT integration into the AXS platform, simplifying diagnosis-to-surgery workflows.
These collaborations underscore Straumann’s commitment to reducing clinical complexity while enhancing the efficiency and affordability of care.
Product Launches Reinforce Market Differentiation
Straumann also marked the global launch of its iEXCEL implant system, previously introduced in North America. The iEXCEL system integrates four implant designs into a single surgical kit and features the clinically proven Roxolid material and SLActive surface for faster osseointegration.
In the EMEA region, Straumann introduced:
- Falcon: A compact, dynamic navigation system for real-time surgical guidance.
- UN!Q: Now available regionally to support customized, digitally manufactured restorations.
These innovations are aligned with the company’s strategy to deliver a premium, digitally enhanced, and accessible solution portfolio.
AGM Approval Reinforces Shareholder Confidence
At its Annual General Meeting on April 10, shareholders approved all Board proposals, including a CHF 0.95 dividend per share, paid on April 16. The vote reflects continued investor confidence in Straumann’s growth strategy and financial performance.
2025 Outlook Reaffirmed as Group Targets Continued Market Share Gains
Straumann Group remains focused on long-term, profitable growth, despite persistent global macroeconomic headwinds. With a diversified portfolio across price points, global manufacturing capabilities, and sustained investments in clinician education and digital transformation, the Group maintains its goal of:
- High single-digit organic revenue growth
- 30–60 basis point core EBIT margin improvement, at constant 2024 currency rates
Straumann continues to expand its addressable market — estimated at CHF 20 billion — through strategic innovation and operational excellence.
Learn more at www.straumann.com